MicroPort’s Wright Bid Creates New Ortho Player

Wright Medical’s decision to sell its hip and knee business wasn’t entirely unexpected. The buyer, the Chinese company MicroPort, may have surprised some, but changes in orthopedics and the device industry as a whole could make such deals more common.

Wright Medical Group NV’s decision to sell its hip and knee joint business shouldn’t really have surprised anyone. [See Deal] CEO Robert Palmisano – in the eyes of one Wall Street analyst – is a “money maker” who has generated significant returns for investors by guiding businesses like eye company IntraLase Corp. and peripheral vascular player ev3 Inc. into the arms of larger strategic acquirers, Abbott Laboratories Inc.’s Abbott Medical Optics Inc. (then called Advanced Medical Optics) and Covidien Ltd., respectively. [See Deal][See Deal] Wright watchers say Palmisano had set a similar course for Wright when he joined as CEO in 2011. Early on, he divided the company into two distinct businesses, one focusing on the high-growth extremities sector and the other centered on the low-growth large joint sector. Given the divergent fates of the two sectors, it wasn’t difficult to guess which business was on the way out.

The time was right for Wright. Palmisano, in a conference call, told analysts the company has made "significant progress" in building out its extremities business. The company late last year...

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.